Year Founded
2018
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Small molecule

Arpeggio Biosciences General Information

NRF2 degrader showing regression of aggressive adenocarcinoma tumors in vivo

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

NRF2 degrader
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Arpeggio Biosciences's pipeline data

Book a demo

Key Partnerships

40+ pharmaceutical companies for transcription assessment

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Arpeggio Biosciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Arpeggio Biosciences's complete valuation and funding history, request access »

Arpeggio Biosciences Investors

Builders VC
Investor Type: Venture Capital
Holding: Minority
Khosla Ventures
Investor Type: Venture Capital
Holding: Minority
TechU Ventures
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 7 investors. Get the full list »